{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:00:39Z","timestamp":1792710039136,"version":"4.5.0"},"reference-count":40,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Multiple studies have demonstrated that patients with acute myeloid leukemia (AML) who have measurable residual disease (MRD) detected during or after treatment have higher relapse rates and worse survival than similar patients testing negative. Updated response criteria for AML reflect the understanding that achievement of complete remission (CR) with no detectable MRD using high-sensitivity tests represents a superior response over conventional cytomorphological CR alone. Potential use cases for AML MRD testing are diverse and include patient selection for clinical trials and therapeutic assignment, early relapse detection and intervention during sequential monitoring, and drug development, including deep quantification for antileukemia efficacy and as a surrogate endpoint for overall survival in regulatory approvals. Testing for AML MRD has not, however, been harmonized, and many technical and clinical questions remain. The implications of MRD test results for specific therapeutic combinations, molecular subsets, test types, treatment time points, sample types, and patient characteristics remain incompletely defined. No perfect AML MRD test or testing strategy currently exists, and the evidence basis for clinical recommendations in this rare disease is sparse but growing. It is unproven whether conversion of an MRD test result from positive to negative by additional therapeutic intervention improves relapse risk and survival. Several national- and international-level consortia have recently been initiated to advance the generation and collection of evidence to support the use of AML MRD testing in clinical practice, drug development, and regulatory approvals.<\/jats:p>","DOI":"10.1182\/hematology.2022000323","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T16:16:17Z","timestamp":1670602577000},"page":"9-14","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":21,"title":["Achieving MRD negativity in AML: how important is this and how do we get there?"],"prefix":"10.1182","volume":"2022","author":[{"given":"Christopher S.","family":"Hourigan","sequence":"first","affiliation":[{"name":"Laboratory of Myeloid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,12,9]]},"reference":[{"issue":"4","key":"2022121313580946400_hem2022000323C1","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"26","key":"2022121313580946400_hem2022000323C2","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 update measurable residual disease in acute myeloid leukemia: European LeukemiaNet Working Party consensus document","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"issue":"12","key":"2022121313580946400_hem2022000323C3","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"key":"2022121313580946400_hem2022000323C4","article-title":"Minimal Residual Disease in Acute Leukemia","author":"L\u00f6wenberg","year":"1984","edition":"1st"},{"issue":"4","key":"2022121313580946400_hem2022000323C5","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/cyto.990060411","article-title":"Detection of minimal disease in acute leukemia using flow cytometry: studies in a rat model for human acute leukemia","volume":"6","author":"Martens","year":"1985","journal-title":"Cytometry"},{"issue":"4","key":"2022121313580946400_hem2022000323C6","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/0145-2126(83)90049-8","article-title":"BCG treatment of residual disease in acute leukemia: studies in a rat model for human acute myelocytic leukemia (BNML)","volume":"7","author":"Hagenbeek","year":"1983","journal-title":"Leuk Res"},{"issue":"5","key":"2022121313580946400_hem2022000323C7","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3324\/haematol.2016.159343","article-title":"Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis","volume":"102","author":"Buckley","year":"2017","journal-title":"Haematologica"},{"issue":"12","key":"2022121313580946400_hem2022000323C8","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","article-title":"Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis","volume":"6","author":"Short","year":"2020","journal-title":"JAMA Oncol"},{"issue":"5","key":"2022121313580946400_hem2022000323C9","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/s41409-019-0729-4","article-title":"Statistics and measurable residual disease (MRD) testing: uses and abuses in hematopoietic cell transplantation","volume":"55","author":"Othus","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"2022121313580946400_hem2022000323C10","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1038\/leu.2016.120","article-title":"Effect of measurable (\u201cminimal\u201d) residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia","volume":"30","author":"Othus","year":"2016","journal-title":"Leukemia"},{"issue":"8","key":"2022121313580946400_hem2022000323C11","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1038\/s41375-021-01126-3","article-title":"Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia","volume":"35","author":"Paiva","year":"2021","journal-title":"Leukemia"},{"issue":"24","key":"2022121313580946400_hem2022000323C12","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1182\/blood.2021014520","article-title":"Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML","volume":"139","author":"Murdock","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2022121313580946400_hem2022000323C13","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/PPO.0000000000000572","article-title":"Measurable residual disease assessment as a surrogate marker in new drug development in acute myeloid leukemia","volume":"28","author":"Gui","year":"2022","journal-title":"Cancer J"},{"issue":"19","key":"2022121313580946400_hem2022000323C14","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1182\/blood.2019003566","article-title":"How I treat measurable (minimal) residual disease in acute leukemia after allogeneic hematopoietic cell transplantation","volume":"135","author":"Spyridonidis","year":"2020","journal-title":"Blood"},{"issue":"7","key":"2022121313580946400_hem2022000323C15","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1038\/leu.2017.113","article-title":"Measurable residual disease testing in acute myeloid leukaemia","volume":"31","author":"Hourigan","year":"2017","journal-title":"Leukemia"},{"issue":"9","key":"2022121313580946400_hem2022000323C16","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.3390\/cancers12092339","article-title":"Conditioning intensity, pre-transplant flow cytometric measurable residual disease, and outcome in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation","volume":"12","author":"Morsink","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2022121313580946400_hem2022000323C17","author":"Heuser","year":"2021"},{"issue":"1","key":"2022121313580946400_hem2022000323C18","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/bjh.16362","article-title":"Next-generation sequencing for measurable residual disease detection in acute myeloid leukaemia","volume":"188","author":"Ghannam","year":"2020","journal-title":"Br J Haematol"},{"issue":"13","key":"2022121313580946400_hem2022000323C19","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","article-title":"Molecular minimal residual disease in acute myeloid leukemia","volume":"378","author":"Jongen-Lavrencic","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"2022121313580946400_hem2022000323C20","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1200\/JCO.19.03011","article-title":"Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease","volume":"38","author":"Hourigan","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"2022121313580946400_hem2022000323C21","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1038\/s41375-021-01131-6","article-title":"Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML)","volume":"35","author":"Patkar","year":"2021","journal-title":"Leukemia"},{"issue":"2","key":"2022121313580946400_hem2022000323C22","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3324\/haematol.2018.203133","article-title":"Targeted RNA-sequencing for the quantification of measurable residual disease in acute myeloid leukemia","volume":"104","author":"Dillon","year":"2019","journal-title":"Haematologica"},{"issue":"8","key":"2022121313580946400_hem2022000323C23","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.ccell.2022.07.002","article-title":"Integrative analysis of drug response and clinical outcome in acute myeloid leukemia","volume":"40","author":"Bottomly","year":"2022","journal-title":"Cancer Cell"},{"issue":"4","key":"2022121313580946400_hem2022000323C24","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1158\/2643-3230.BCD-21-0046","article-title":"Personalized single-cell proteogenomics to distinguish acute myeloid leukemia from non-malignant clonal hematopoiesis","volume":"2","author":"Dillon","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"7834","key":"2022121313580946400_hem2022000323C25","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41586-020-2864-x","article-title":"Single-cell mutation analysis of clonal evolution in myeloid malignancies","volume":"587","author":"Miles","year":"2020","journal-title":"Nature"},{"issue":"8","key":"2022121313580946400_hem2022000323C26","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1200\/JCO.21.01546","article-title":"Measurable residual disease response and prognosis in treatment-na\u00efve acute myeloid leukemia with venetoclax and azacitidine","volume":"40","author":"Pratz","year":"2022","journal-title":"J Clin Oncol"},{"issue":"14","key":"2022121313580946400_hem2022000323C27","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1182\/blood.2021013404","article-title":"Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status","volume":"139","author":"Roboz","year":"2022","journal-title":"Blood"},{"issue":"7","key":"2022121313580946400_hem2022000323C28","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/bloodadvances.2020003717","article-title":"Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia","volume":"5","author":"Maiti","year":"2021","journal-title":"Blood Adv"},{"issue":"12","key":"2022121313580946400_hem2022000323C29","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S1470-2045(18)30580-1","article-title":"Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial","volume":"19","author":"Platzbecker","year":"2018","journal-title":"Lancet Oncol"},{"issue":"9","key":"2022121313580946400_hem2022000323C30","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/ajh.25211","article-title":"Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: a registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation","volume":"93","author":"Gilleece","year":"2018","journal-title":"Am J Hematol"},{"issue":"9","key":"2022121313580946400_hem2022000323C31","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1182\/bloodadvances.2021004367","article-title":"Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations","volume":"5","author":"Heuser","year":"2021","journal-title":"Blood Adv"},{"issue":"11","key":"2022121313580946400_hem2022000323C32","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1182\/blood.2021014804","article-title":"Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML","volume":"139","author":"Paras","year":"2022","journal-title":"Blood"},{"issue":"7","key":"2022121313580946400_hem2022000323C33","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1200\/JCO.20.02308","article-title":"Augmented reduced-intensity regimen does not improve postallogeneic transplant outcomes in acute myeloid leukemia","volume":"39","author":"Craddock","year":"2021","journal-title":"J Clin Oncol"},{"issue":"12","key":"2022121313580946400_hem2022000323C34","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1182\/blood.2018886960","article-title":"GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia","volume":"134","author":"Venditti","year":"2019","journal-title":"Blood"},{"issue":"9","key":"2022121313580946400_hem2022000323C35","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1182\/blood.2019002959","article-title":"Molecular MRD status and outcome after transplantation in NPM1-mutated AML","volume":"135","author":"Dillon","year":"2020","journal-title":"Blood"},{"issue":"26","key":"2022121313580946400_hem2022000323C36","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1182\/blood.2020005998","article-title":"Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial","volume":"136","author":"Kapp-Schwoerer","year":"2020","journal-title":"Blood"},{"issue":"16","key":"2022121313580946400_hem2022000323C37","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-02-829911","article-title":"Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML","volume":"132","author":"Thol","year":"2018","journal-title":"Blood"},{"issue":"suppl 16","key":"2022121313580946400_hem2022000323C38","doi-asserted-by":"crossref","first-page":"7006","DOI":"10.1200\/JCO.2022.40.16_suppl.7006","article-title":"Pre-MEASURE: multicenter evaluation of the prognostic significance of measurable residual disease testing prior to allogeneic transplantation for adult patients with AML in first remission","volume":"40","author":"Hourigan","year":"2022","journal-title":"J Clin Oncol"},{"key":"2022121313580946400_hem2022000323C39","unstructured":"US Food and Drug Administration. Hematologic malignancies: regulatory considerations for use of minimal residual disease in development of drug and biological products for treatment. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/hematologic-malignancies-regulatory-considerations-use-minimal-residual-disease-development-drug-and."},{"key":"2022121313580946400_hem2022000323C40","unstructured":"Johnson and Johnson. MPAACT consortium unites industry and academia to establish measurable residual disease as a surrogate endpoint in acute myeloid leukemia drug development. https:\/\/www.jnj.com\/mpaact -consortium-unites-industry-and-academia-to-establish-measurable -residual-disease-as-a-surrogate-endpoint-in-acute-myeloid-leukemia -drug-development."}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2022\/1\/9\/2022934\/9hourigan.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2022\/1\/9\/2022934\/9hourigan.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T13:58:35Z","timestamp":1670939915000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2022\/1\/9\/493487\/Achieving-MRD-negativity-in-AML-how-important-is"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,9]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12,9]]},"published-print":{"date-parts":[[2022,12,9]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2022000323","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,9]]},"published":{"date-parts":[[2022,12,9]]}}}